Posts tagged cholesterol 24-hydroxylase inhibitor
WB starts Ovid at OP

William Blair initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with an “outperform” rating and fair value estimate of $28. The stock closed at $14.57 on May 26.

Read More